paclitaxel has been researched along with Leukemia, Prolymphocytic in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abrams, SL; Bäsecke, J; Chappell, W; Donia, M; Libra, M; Martelli, AM; McCubrey, JA; Nicoletti, F; Shelton, JG; Steelman, LS; Stivala, F | 1 |
1 other study(ies) available for paclitaxel and Leukemia, Prolymphocytic
Article | Year |
---|---|
Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Chromones; Doxorubicin; G1 Phase; Interleukin-3; Intracellular Signaling Peptides and Proteins; Leukemia, Prolymphocytic; Mice; Mitogen-Activated Protein Kinase Kinases; Morpholines; Nitriles; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2010 |